Vitiligo
Clinical guidelines for managing autoimmune depigmentation, stabilizing active pigment loss, and evaluating targeted JAK inhibitors.
Table of Contents
🧠 Standard of Care & Symptoms
Vitiligo is a chronic autoimmune disorder that causes areas of skin to lose their natural pigment (melanin). This happens because the body's immune system attacks and destroys pigment-producing cells called melanocytes.
- Presentation: Milk-white, flat patches on the skin with distinct borders. Hair growing in affected areas may also turn white. It most frequently occurs around body openings (mouth, eyes), fingers, wrists, armpits, and groin.
- Classification:
- Non-Segmental Vitiligo: The most common form, presenting bilaterally and symmetrically across the body. It progresses periodically over a lifetime.
- Segmental Vitiligo: Affects only one segment or side of the body, usually occurring early in life and stabilizing rapidly.
- Systemic Association: Patients have a higher risk of other concurrent autoimmune diseases, particularly autoimmune thyroiditis (Hashimoto's or Graves' disease), Type 1 Diabetes, and Rheumatoid Arthritis.
💊 Topical & Phototherapy Regimens
First-line therapies focus on halting active spread and encouraging repigmentation by stimulating remaining melanocytes in hair follicles.
Topical Immunomodulators
- Corticosteroids: Mid- to high-potency topical steroids are first-line for localized vitiligo to suppress early immune activity. Caution must be taken to avoid skin atrophy on thin skin areas like the face.
- Calcineurin Inhibitors: Tacrolimus ointment or Pimecrolimus cream are non-steroidal immunomodulators preferred for facial and intertriginous areas.
Phototherapy
- Narrowband UVB (NB-UVB): The gold standard treatment for widespread vitiligo, administered 2 to 3 times weekly. It suppresses local immune cells and stimulates follicular melanocytes to migrate and repigment patches.
🔬 Advanced JAK Treatments
Targeted Janus Kinase (JAK) inhibition represents a paradigm shift, directly blocking the interferon-gamma (IFN-γ) signaling pathway that drives melanocyte destruction.
- Ruxolitinib (Opzelura): The first FDA-approved topical JAK1/JAK2 inhibitor cream for non-segmental vitiligo in patients 12 and older. It demonstrates significant facial and body repigmentation when applied twice daily over 24 to 52 weeks.
- Oral JAK Inhibitors: Systemic JAK inhibitors are currently undergoing clinical trials to halt rapidly progressive vitiligo.
📊 Measuring Repigmentation: The VASI Score
Dermatologists and researchers track the progress of repigmentation treatments using the **Vitiligo Area Scoring Index (VASI)**. This measurement evaluates both the body surface area affected and the degree of depigmentation within each patch:
- Calculation: The VASI is calculated by dividing the body into six regions (hands, feet, upper limbs, lower limbs, trunk, and head/neck). For each region, the percentage of vitiligo involvement (using the patient's palm size as representing 1% BSA) is multiplied by the pigment loss percentage (ranging from 0% for normal pigment, to 100% for complete depigmentation).
- Treatment Goals (F-VASI & T-VASI):
- F-VASI 75: A 75% or greater improvement in the facial VASI score. Achieving F-VASI 75 is a primary clinical trial endpoint, representing a major aesthetic improvement.
- T-VASI 50: A 50% or greater improvement in the total body VASI score, indicating widespread pigment restoration.
🔬 Active Clinical Trials
Clinical trials are currently investigating oral JAK inhibitors for systemic stabilization, interleukin-15 (IL-15) blockers, and surgical grafting combinations.
Evaluating the efficacy of an oral JAK inhibitor in stabilizing rapidly progressive non-segmental vitiligo.
Key Inclusion: Age 18 to 65, diagnosis of active non-segmental vitiligo with clinically documented spread within the past 3 months, and total body vitiligo involvement ≥ 5% BSA.Evaluating the safety and repigmentation efficacy of a humanized anti-IL-15 receptor monoclonal antibody.
Key Inclusion: Stable or slowly progressive non-segmental vitiligo with ≥ 1% facial involvement, failed at least one topical treatment, and no phototherapy for ≥ 3 months.Evaluating outcomes of combining cellular micrografting (melanocyte-keratinocyte transplant) with topical Ruxolitinib.
Key Inclusion: Stable vitiligo (no new patches or spreading for ≥ 12 months), localized segment or patches suitable for donor harvesting.🗺️ Next Steps After Diagnosis
If you have recently been diagnosed with Vitiligo, follow these guidelines to manage the condition:
- Discuss Thyroid Screening: Request thyroid function and antibody tests (TSH, free T4, TPO antibodies) from your doctor to rule out thyroid disease.
- Practice Sun Safety: Depigmented skin lacks protective melanin and burns easily, increasing skin cancer risk. Apply broad-spectrum mineral SPF 30+ daily and avoid sun exposure during peak hours.
- Avoid Physical Trauma (Koebner Phenomenon): Scrapes, cuts, or friction can cause new vitiligo patches to form on the injured skin site. Avoid tight clothing and abrasive scrubbing.
- Explore Cosmetic Camouflage: High-coverage skin cover-ups or self-tanners containing dihydroxyacetone (DHA) can safely mask white patches if desired.
❓ Patient FAQ
Q: Can vitiligo patches spread over time?
A: Yes. Non-segmental vitiligo typically has a fluctuating course with periods of stability followed by active spreading, often triggered by stress or skin injury.
Q: Can vitiligo be cured?
A: There is currently no cure for vitiligo, but treatments can halt active progression and restore pigment to many areas of the skin, particularly the face and neck.
Get the Free 2026 Clinical AI Directory
Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.